Intrasense, a French expert in medical imaging solutions facilitating and securing diagnosis, decision-making, and treatment follow-up, announces the publication of its 2026 half-year results and progress on its strategic roadmap.

Intrasense, a French specialist in AI-enhanced medical imaging solutions supporting diagnosis, clinical decision-making and therapeutic monitoring ("Intrasense" or the "Company"), announces that it has received a firm and irrevocable offer from EDL for the acquisition of its Myrian® business.

Intrasense, a French expert in AI enhanced medical imaging solutions facilitating diagnosis, decision-making and therapeutic follow-up, announces that on 19 June 2026 it entered into with Guerbet a second amendment to the shareholder current account advance agreement dated 1 October 2024 for an amount of €2.4 million (the ‘Advance No. 1’) and an amendment to the
shareholder current account advance agreement dated 7 February 2025 for an amount of €5.6 million (the ‘Advance
No. 2’), in order to defer the repayment date of Advance No. 1 and Advance No. 2 from 30 June 2026 to 30 June 2027

Intrasense, a French expert in AI-enhanced medical imaging solutions facilitating diagnosis, decision-making and therapeutic follow-up, and Guerbet, a global leader in medical imaging, announce that DUOnco™ Pancreas has obtained PMDA certification in Japan under certification number 308AGBZI00003000 (Class II, Classification: Program 1 Disease Diagnostic Program, Program for X-ray imaging diagnostic device workstations (JMDN code: 40935012)). With this certification, DUOnco™ Pancreas becomes to our knowledge the first AI software focused on the pancreas to be certified in Japan.

Intrasense, a French expert in AI-powered medical imaging solutions that facilitate diagnosis, decision-making, and therapeutic follow-up, announces the publication of its 2025 annual results. These financial statements were approved by the Board of Directors on March 10, 2026.